东睦新材料集团股份有限公司重大资产重组最新进展公告
一、公告概要
东睦新材料集团股份有限公司（股票代码：600114，简称“东睦股份”）于2026年4月23日发布公告，披露公司拟通过发行股份及支付现金的方式，向五名交易对方购买上海富驰高科技股份有限公司34.75%股权，并募集配套资金。此次交易涉及的交易对方包括深圳市远致星火私募股权投资基金合伙企业（有限合伙）、钟伟、上海创精投资咨询合伙企业（有限合伙）、宁波华莞企业管理合伙企业（有限合伙）、宁波富精企业管理合伙企业（有限合伙）。
二、交易细节与流程
- 东睦股份拟通过发行股份及支付现金的方式收购上海富驰高科技股份有限公司34.75%股权。
- 交易完成后，公司还将募集配套资金。
- 此次交易属于关联交易，需遵循相关监管规定。
- 本次交易已提交上海证券交易所（上交所）并购重组审核委员会审查，并列入2026年第4次审议会议议程，会议将于2026年4月29日召开。
- 交易尚需获得中国证券监督管理委员会同意注册后方可实施。
- 交易能否取得批准及注册，以及最终取得批准和注册的时间均存在不确定性。
三、对投资者的影响与风险提示
- 重大资产重组：公司拟大规模收购上海富驰高科技股份有限公司股权，这可能对公司未来的业务布局、盈利能力及市场竞争力带来显著影响。
- 价格敏感信息：此次交易涉及发行股份、支付现金及募集配套资金，属于重大资产重组事项，对公司股价可能产生影响。
- 交易存在不确定性：交易尚需上交所审核通过及证监会注册，存在审批不通过的风险，投资者需密切关注后续信息披露。
- 关联交易：此次交易涉及关联方，需关注关联方利益冲突及相关合规风险。
- 信息披露承诺：公司承诺将根据交易进展，严格按照规定，及时履行信息披露义务。
四、公司声明
董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对内容真实性、准确性和完整性承担责任。
五、投资者关注要点
- 该重组事项属重大资产交易，可能直接影响公司股价及未来经营业绩。
- 投资者应密切关注后续监管审批进展，注意投资风险。
- 公司后续将就交易进展及时公告，请投资者关注公司公告及市场动态。
免责声明
本文章内容仅供参考，不构成任何投资建议。投资者应根据自身风险承受能力，审慎决策。公司交易事项尚存审批及注册不确定性，股价可能受此事件影响。敬请投资者注意相关风险。
NBTM New Materials Group Co., Ltd. Major Asset Restructuring Progress Announcement
1. Summary of Announcement
NBTM New Materials Group Co., Ltd. (Stock Code: 600114, “NBTM”) announced on April 23, 2026, that it plans to acquire 34.75% equity of Shanghai Fuchi High-Tech Co., Ltd. from five counterparties via share issuance and cash payment, and to raise supporting funds. The counterparties include Shenzhen Yuanzhi Xinghuo Private Equity Fund Partnership (Limited Partnership), Zhong Wei, Shanghai Chuangjing Investment Consulting Partnership (Limited Partnership), Ningbo Huaguan Enterprise Management Partnership (Limited Partnership), and Ningbo Fujing Enterprise Management Partnership (Limited Partnership).
2. Transaction Details and Process
- NBTM proposes to acquire 34.75% equity in Shanghai Fuchi High-Tech Co., Ltd. via share issuance and cash payment.
- Supporting funds will be raised following the completion of the transaction.
- This is a related-party transaction and must comply with regulatory requirements.
- The transaction has been submitted to the Shanghai Stock Exchange (SSE) Merger and Acquisition Review Committee and is scheduled for review at the 4th meeting in 2026, to be held on April 29, 2026.
- The transaction must also be registered with the China Securities Regulatory Commission (CSRC) to be implemented.
- There is uncertainty regarding the approval and registration, and the timeline for completion is not guaranteed.
3. Impact on Investors and Risk Warning
- Major Asset Restructuring: The company plans a significant acquisition, which may have a material impact on its future business layout, profitability, and market competitiveness.
- Price-Sensitive Information: The transaction involves share issuance, cash payments, and fundraising, constituting a major asset restructuring that could affect the company’s share price.
- Uncertainty: The transaction is subject to SSE and CSRC approval; if not granted, the deal will not proceed. Investors should closely follow subsequent disclosures.
- Related-Party Transaction: This deal involves related parties, so investors should monitor for potential conflicts of interest and compliance risks.
- Disclosure Commitment: The company commits to timely and compliant information disclosure as developments occur.
4. Company Statement
The Board of Directors and all directors guarantee the authenticity, accuracy, and completeness of the announcement, with no false statements, misleading representations, or material omissions.
5. Key Points for Investors
- This is a major asset transaction that could directly impact the company’s share price and future performance.
- Investors should closely monitor regulatory approval progress and be aware of investment risks.
- The company will announce further progress as it occurs; investors are advised to follow company announcements and market trends.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should make prudent decisions based on their own risk tolerance. The transaction is subject to regulatory approval and registration, which may affect share price. Please be cautious regarding related risks.
View 东睦股份 Historical chart here
